Study Of GW679769 In Major Depressive Disorder

Completed · Phase 2

Conditions studied: Depressive Disorder, Major, Major Depressive Disorder (MDD)

In brief

This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.

Key facts

Study ID

NCT00102492

Run by

GlaxoSmithKline

People needed

356

Starts

2004-10-01

Expected to finish

2006-09-01

Last updated by the study team

2015-04-16

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must have the ability to comprehend the key components of the consent form.
• Subject must have met DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) criteria for current MDE (major depressive episode) for at least 8 weeks prior to the Screening Visit.
• If female, subjects must be practicing an acceptable method of birth control.
• Subjects must have rating scores as outlined.

You may not qualify if…

• Subjects whose symptoms of the MDE are better accounted for by another diagnosis.
• Subjects with a history of schizophrenia, schizoaffective disorders or bipolar disorder.
• Subjects have a positive urine test for illicit drug use and/or a history of substance abuse or alcohol dependence within the past 12 months.
• Subjects with an unstable medical disorder.
• If female, pregnant or lactating.
• Subjects who have received ECT (electroconvulsive therapy) or TMS (transcranial magnetic stimulation) within the 6 months preceding screening or who have ever been homicidal.

Where it is running

• GSK Investigational Site — Scottsdale, Arizona, United States
• GSK Investigational Site — Little Rock, Arkansas, United States
• GSK Investigational Site — Beverly Hills, California, United States
• GSK Investigational Site — Fort Lauderdale, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — North Miami, Florida, United States
• GSK Investigational Site — Orlando, Florida, United States
• GSK Investigational Site — Winter Park, Florida, United States
• GSK Investigational Site — Marietta, Georgia, United States
• GSK Investigational Site — Smyrna, Georgia, United States
• GSK Investigational Site — Oakbrook Terrace, Illinois, United States
• GSK Investigational Site — Shreveport, Louisiana, United States
• GSK Investigational Site — Rockville, Maryland, United States
• GSK Investigational Site — Farmington Hills, Michigan, United States
• GSK Investigational Site — Saint Charles, Missouri, United States
• GSK Investigational Site — Clementon, New Jersey, United States
• GSK Investigational Site — Brooklyn, New York, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Beachwood, Ohio, United States
• GSK Investigational Site — Eugene, Oregon, United States
• GSK Investigational Site — Portland, Oregon, United States
• GSK Investigational Site — Memphis, Tennessee, United States
• GSK Investigational Site — Austin, Texas, United States
• GSK Investigational Site — Irving, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.